1,759 results on '"Rammensee, Hans-Georg"'
Search Results
152. Argyrin F Treatment‐Induced Vulnerabilities Lead to a Novel Combination Therapy in Experimental Glioma
153. NKp80 defines and stimulates a reactive subset of CD8 T cells
154. Allele-Specific Peptide Ligand Motifs of HLA-C Molecules
155. Murine Epidermal Langerhans Cells Express Significant Amounts of Class I Major Histocompatibility Complex Antigens
156. Characterization of Naturally Occurring Minor Histocompatibility Peptides Including H-4 and H-Y
157. TLR9 independent interferon α production by neutrophils on NETosis in response to circulating chromatin, a key lupus autoantigen
158. Cutaneous Innate Immune Sensing of Toll-like Receptor 2–6 Ligands Suppresses T Cell Immunity by Inducing Myeloid-Derived Suppressor Cells
159. Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy
160. Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer
161. Mass spectrometry for quality control of bispecific antibodies after SDS‐PAGE in‐gel digestion
162. The dominantly expressed class II molecule from a resistant MHC haplotype presents only a few Marek’s disease virus peptides by using an unprecedented binding motif
163. T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals
164. HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy
165. Deoxyribonuclease 1-Mediated Clearance of Circulating Chromatin Prevents From Immune Cell Activation and Pro-inflammatory Cytokine Production, a Phenomenon Amplified by Low Trap1 Activity: Consequences for Systemic Lupus Erythematosus
166. Expression levels of HLA-DR in acute myeloid leukemia: implications for antigenicity and clinical outcome
167. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
168. Deoxyribonuclease 1-Mediated Clearance of Circulating Chromatin Prevents From Immune Cell Activation and Pro-inflammatory Cytokine Production, a Phenomenon Amplified by Low Trap1 Activity: Consequences for Systemic Lupus Erythematosus
169. HLA ligand profiles of primary renal cell carcinoma maintained in metastases
170. IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism
171. Potent costimulation of human CD8 T cells by anti-4-1BB and anti-CD28 on synthetic artificial antigen presenting cells
172. Obituary: Dr Zoltan A. Nagy (1941–2020)
173. Pre-existing and post-COVID-19 immune responses to SARS-CoV-2 in cancer patients
174. The Peptide Vaccine of the Future
175. Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival
176. HLA ligandome tumor antigen discovery for personalized vaccine approach
177. An IgG‐based bispecific antibody for improved dual targeting in PSMA‐positive cancer
178. The Impact of Biomaterial Cell Contact on the Immunopeptidome
179. Immunotherapy of renal cell carcinoma
180. HLA Evolutionary Divergence as a Prognostic Marker for AML Patients Undergoing Allogeneic Stem Cell Transplantation
181. Comparative Analysis of Volatile Constituents from Mice and their Urine
182. Identification of HLA-DR-bound peptides presented by human bronchoalveolar lavage cells in sarcoidosis
183. SNEP: SNP-derived Epitope Prediction program for minor H antigens
184. Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy
185. CD8+ T-cell response against MUC1-derived peptides in gastrointestinal cancer survivors
186. Identification of an antigenic peptide derived from the cancer-testis antigen NY-ESO-1 binding to a broad range of HLA-DR subtypes
187. Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling
188. The Tübingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy
189. Differential host response to a herpesvirus: Marek’s disease virus peptides on chicken MHC class II molecules are derived from only a few genes and illustrate a new mode of peptide binding
190. Differential kinetics of T cell and antibody responses delineate dominant T cell epitopes in long-term immunity after COVID-19
191. HLA-DR15 Molecules Jointly Shape an Autoreactive T Cell Repertoire in Multiple Sclerosis
192. Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial
193. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition
194. Global Analysis of the Mammalian MHC class I Immunopeptidome at the Organism-Wide Scale
195. HLA-DR15-derived self-peptides are involved in increased autologous T cell proliferation in multiple sclerosis
196. Possible association of non-binding of HSP70 to HLA-DRB1 peptide sequences and protection from rheumatoid arthritis
197. Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines
198. Impaired tumor rejection by memory CD8 T cells in mice with NKG2D dysfunction
199. PAProC: a prediction algorithm for proteasomal cleavages available on the WWW
200. Two new proteases in the MHC class I processing pathway
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.